Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Anti-Xa Levels With Nadroparin as Thrombosis Prophylaxis in COVID-19 and Non-COVID-19 Patients Admitted at the ICU

NCT05926518 is registered in ClinicalTrials.gov with Rijnstate Hospital as lead sponsor.

NCT NCT05926518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05926518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Anti-Xa Levels With Nadroparin as Thrombosis Prophylaxis in COVID-19 and Non-COVID-19 Patients Admitted at the ICU
Lead sponsor
Rijnstate Hospital
Phase
Observational
Overall status
Completed
Start date
November 1, 2020
Completion date
November 23, 2022
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

critical illness, therapeutic drug monitoring, venous thromboembolism